

# Louis Aledort

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/100441/publications.pdf>

Version: 2024-02-01

116  
papers

1,926  
citations

567281

15  
h-index

265206

42  
g-index

132  
all docs

132  
docs citations

132  
times ranked

1645  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | In response to WFH guidelines for the management of haemophilia, 3 <sup>rd</sup> edition: Is there a difference between extendedâ€½life FVIII products or not?. Haemophilia, 2021, 27, e762-e764. | 2.1  | 0         |
| 2  | Deaths Associated with Emicizumab in Patients with Hemophilia A. New England Journal of Medicine, 2019, 381, 1878-1879.   | 27.0 | 20        |
| 3  | Why plasmaâ€½derived factor VIII?. Haemophilia, 2019, 25, e183-e185.  | 2.1  | 0         |
| 4  | The ongoing imperative for immune tolerance induction in inhibitor management. Haemophilia, 2019, 25, 183-186.  | 2.1  | 9         |
| 5  | Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfusion, 2019, 17, 479-486.   | 0.4  | 53        |
| 6  | Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis. Journal of Immunological Methods, 2018, 453, 11-19.        | 1.4  | 11        |
| 7  | Evaluating the safety of emicizumab in patients with hemophilia A. Expert Opinion on Drug Safety, 2018, 17, 1233-1237.  | 2.4  | 15        |
| 8  | Prophylaxis reâ€½visited: The potential impact of novel factor and nonâ€½factor therapies on prophylaxis. Haemophilia, 2018, 24, 845-848.   | 2.1  | 5         |
| 9  | An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia. Haemophilia, 2017, 23, e444-e447.                            | 2.1  | 3         |
| 10 | An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia. Haemophilia, 2017, 23, e447-e450.  | 2.1  | 4         |
| 11 | Treatment of Congenital Thrombotic Thrombocytopenia Purpura: A New Paradigm. Journal of Pediatric Hematology/Oncology, 2017, 39, 524-527.   | 0.6  | 14        |
| 12 | The Role of Platelet Activation and Inflammation in Early Brain Injury Following Subarachnoid Hemorrhage. Neurocritical Care, 2017, 26, 48-57.  | 2.4  | 112       |
| 13 | Hemophilia Lend-Lease Program in Italy Successfully Meets Albania Factor Needs. Blood, 2016, 128, 5916-5916.  | 1.4  | 1         |
| 14 | Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged â‰¥65Â½years with immune thrombocytopenia. Annals of Hematology, 2015, 94, 1973-1980.                     | 1.8  | 25        |
| 15 | Factor VIII therapy for hemophilia A: current and future issues. Expert Review of Hematology, 2014, 7, 373-385.   | 2.2  | 27        |
| 16 | A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood, 2014, 123, 3887-3894.                           | 1.4  | 112       |
| 17 | Managing incidentally diagnosed isolated factor VII deficiency perioperatively: a brief expert consensus report. Expert Review of Hematology, 2012, 5, 47-50.                                     | 2.2  | 8         |
| 18 | Why should we care about quality of life in persons with haemophilia?. Haemophilia, 2012, 18, e154-7.   | 2.1  | 34        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Tertiary prophylaxis in adults: is there a rationale?. Haemophilia, 2012, 18, 722-728.  | 2.1 | 26        |
| 20 | The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. Journal of Thrombosis and Haemostasis, 2011, 9, 2229-2234.                    | 3.8 | 42        |
| 21 | Acquired hemophilia: We now see it with myeloproliferative neoplasms. American Journal of Hematology, 2011, 86, 329-330.  | 4.1 | 8         |
| 22 | <i>Expert Review of Hematology:</i>addressing the needs of a broad research field. Expert Review of Hematology, 2008, 1, 1-2.   | 2.2 | 1         |
| 23 | Hemophilia lives: the impact of prophylaxis. Blood, 2008, 111, 1752-1753.   | 1.4 | 1         |
| 24 | Hemophilia Treatment - A Model for Appropriate Cost Control.. Blood, 2007, 110, 3942-3942.  | 1.4 | 0         |
| 25 | Do hemophilia carriers bleed? Yes.. Blood, 2006, 108, 6-6.  | 1.4 | 12        |
| 26 | The Clinical and Direct Medical Cost Burden of Splenectomy among Managed Care Patients with Chronic Immune Thrombocytopenic Purpura (ITP).. Blood, 2006, 108, 5536-5536.  | 1.4 | 2         |
| 27 | Retrospective Matched Cohort Study of Immune Thrombocytopenic Purpura (ITP): Complications Related to Corticosteroid (CS) Use.. Blood, 2006, 108, 3295-3295.  | 1.4 | 24        |
| 28 | Plug the hole. Blood, 2005, 105, 2621-2621.   | 1.4 | 1         |
| 29 | United States' factor XI-deficiency patients need a safer treatment. American Journal of Hematology, 2005, 80, 301-302.   | 4.1 | 12        |
| 30 | Adverse Events (AEs): Are They Factored into Costs of Hemophilia Care?.. Blood, 2005, 106, 5550-5550.   | 1.4 | 0         |
| 31 | Can Health Care Plans Afford Hemophilia Costs? Yes.. Blood, 2005, 106, 5551-5551.   | 1.4 | 0         |
| 32 | Platelet bleeding disorders and approach to their management. Psychophysiology, 2005, 4, 85-7.  | 1.1 | 0         |
| 33 | An Open Label, Multi Center Study on the Efficacy and Safety of a Liquid, Ready-to-Use Intravenously Administered Anti-D Immunoglobulin in Patients with Chronic Immune Thrombocytopenic Purpura.. Blood, 2004, 104, 3943-3943. | 1.4 | 12        |
| 34 | Do we need a better test? Can thrombin generation be useful?. Psychophysiology, 2004, 3, 75-6.  | 1.1 | 0         |
| 35 | Orthopedic Outcome Studies and Cost Issues. Seminars in Thrombosis and Hemostasis, 2003, 29, 055-060.   | 2.7 | 4         |
| 36 | Why Thrombin Generation? From Bench to Bedside. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 2-3.   | 0.3 | 12        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Can costs of hemophilia products be curtailed? Not as we do business today!. Thrombosis and Haemostasis, 2002, 88, 541.  | 3.4  | 1         |
| 38 | Definitions in Hemophilia. Thrombosis and Haemostasis, 2001, 85, 560-560.  | 3.4  | 679       |
| 39 | Adverse reactions related to rVlla?. American Journal of Hematology, 2001, 67, 213-213.  | 4.1  | 4         |
| 40 | The above letter was sent to Dr. Aledort, who offered the following reply.. Transfusion, 2000, 40, 495-496.  | 1.6  | 0         |
| 41 | Prophylactic Use of Factor VIII: an Economic Evaluation. Thrombosis and Haemostasis, 1998, 79, 932-937.  | 3.4  | 88        |
| 42 | von Willebrand Disease: From the Bedside to Therapy. Thrombosis and Haemostasis, 1997, 78, 562-565.  | 3.4  | 3         |
| 43 | Inhibitors to Coagulation: Can We Afford Immune Tolerance Induction Regimens?. Vox Sanguinis, 1996, 70, 77-78.   | 1.5  | 3         |
| 44 | Medical necessity-a threat to treatment of chronic disease. Transfusion, 1995, 35, 712-712.  | 1.6  | 0         |
| 45 | Causes of death in haemophilia. Nature, 1995, 378, 124-124.  | 27.8 | 8         |
| 46 | Some Aspects on the Management of Hemophilia. Thrombosis and Haemostasis, 1995, 74, 440-443.   | 3.4  | 6         |
| 47 | Hepatitis A Virus Transmission by Blood Products in the United States. Vox Sanguinis, 1994, 67, 24-28.   | 1.5  | 9         |
| 48 | Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. British Journal of Haematology, 1990, 76, 238-241.                                | 2.5  | 40        |
| 49 | Human Recombinant DNAâ€œDerived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A. New England Journal of Medicine, 1990, 323, 1800-1805.               | 27.0 | 261       |
| 50 | New Approaches to Management of Bleeding Disorders. Hospital Practice (1995), 1989, 24, 207-226.   | 1.0  | 8         |
| 51 | Reproductive choices in hemophilic men and carriers. American Journal of Medical Genetics Part A, 1987, 26, 591-598.   | 2.4  | 23        |
| 52 | Concurrence of von Willebrand's disease and hemophilia A: Implications for carrier detection and prevalence. American Journal of Medical Genetics Part A, 1986, 24, 83-94. | 2.4  | 13        |
| 53 | AIDS: An Update. Hospital Practice (1995), 1983, 18, 159-171.  | 1.0  | 10        |
| 54 | Current Concepts in Diagnosis and Management of Hemophilia. Hospital Practice (1995), 1982, 17, 77-92.   | 1.0  | 14        |

| #  | ARTICLE  | IF | CITATIONS |
|----|--|----|-----------|
| 55 | Women and Von Willebrand Disease. , 0, , 296-301.  |    | 0         |
| 56 | Products Used to Treat Hemophilia: Plasma-Derived Coagulation Factor Concentrates. , 0, , 142-146. |    | 0         |
| 57 | Inhibitors to Factor VIIIâ€™Epidemiology and Treatment. , 0, , 64-70.                              |    | 15        |
| 58 | Von Willebrand Disease: Molecular Aspects. , 0, , 257-264.   |    | 0         |
| 59 | Treatment of Inhibitors in Hemophilia B. , 0, , 101-105.   |    | 3         |
| 60 | Inhibitors in Hemophilia B. , 0, , 97-100.   |    | 16        |
| 61 | Factor X and Factor X Deficiency. , 0, , 315-320.  |    | 1         |
| 62 | Factor XI Deficiency. , 0, , 321-327.  |    | 2         |
| 63 | Inhibitors to Factor VIIIâ€™Molecular Basis. , 0, , 59-63.   |    | 5         |
| 64 | Inhibitors to Factor VIIIâ€™Mild and Moderate Hemophilia. , 0, , 71-73.                            |    | 4         |
| 65 | Inhibitors to Factor VIII/IX: Treatment of Inhibitorsâ€™Immune Tolerance Induction. , 0, , 74-79.  |    | 8         |
| 66 | Inhibitors of Factor VIII: Treatment of Acute Bleeds. , 0, , 80-85.                                |    | 8         |
| 67 | Acquired Inhibitors to Factor VIII. , 0, , 86-90.  |    | 4         |
| 68 | Hemophilia Bâ€™Molecular Basis. , 0, , 91-95.  |    | 2         |
| 69 | Cellular Processing of Factors VIII and IX. , 0, , 5-12.   |    | 0         |
| 70 | Work-Up of a Bleeding Child. , 0, , 112-119.   |    | 0         |
| 71 | Care of the Child with Hemophilia. , 0, , 120-124.   |    | 1         |
| 72 | The Neonate with Hemophilia. , 0, , 125-130.   |    | 4         |

| #  | ARTICLE   | IF | CITATIONS |
|----|---|----|-----------|
| 73 | Products used to Treat Hemophilia: Evolution of Treatment for Hemophilia A and B. , 0, , 131-135.       |    | 5         |
| 74 | Products used to Treat Hemophilia: Recombinant Products. , 0, , 136-141.                                |    | 0         |
| 75 | Products used to Treat Hemophilia: Recombinant Factor Vlla. , 0, , 147-152.                             |    | 3         |
| 76 | Products used to Treat Hemophilia: Dosing. , 0, , 153-157.  |    | 1         |
| 77 | Products Used to Treat Hemophilia: Regulation. , 0, , 158-163.  |    | 0         |
| 78 | Joint Replacement. , 0, , 164-168.  |    | 2         |
| 79 | Work-Up of a Bleeding Adult. , 0, , 13-18.  |    | 0         |
| 80 | Synoviorthesis in Hemophilia. , 0, , 169-173.   |    | 4         |
| 81 | Pseudotumors in Patients with Hemophilia. , 0, , 174-176.   |    | 4         |
| 82 | Magnetic Resonance Imaging/Joint Outcome Assessment. , 0, , 182-192.                                    |    | 2         |
| 83 | Physiotherapy in the Management of Hemophilia. , 0, , 193-199.  |    | 1         |
| 84 | Transfusion Transmitted Disease: History of Epidemics (Focus on HIV). , 0, , 200-206.                   |    | 3         |
| 85 | Transfusion Transmitted Disease: Hepatitis C Virus Infection and Liver Transplantation. , 0, , 207-213. |    | 1         |
| 86 | Gene Therapy: Introduction and Overview. , 0, , 214-219.  |    | 0         |
| 87 | Gene Therapy for Hemophilia B. , 0, , 220-225.  |    | 0         |
| 88 | Gene Therapy for Hemophilia A. , 0, , 226-228.  |    | 3         |
| 89 | Molecular Basis of Hemophilia A. , 0, , 19-26.  |    | 0         |
| 90 | Gene Therapy: Molecular Engineering of Factor VIII and Factor IX. , 0, , 229-234.                       |    | 0         |

| #   | ARTICLE   | IF | CITATIONS |
|-----|---|----|-----------|
| 91  | Laboratory Assays in Hemophilia. , 0 , 235-241.   |    | 6         |
| 92  | Standardization of Assays. , 0 , 242-248.   |    | 3         |
| 93  | Obstetrics and Gynecology: Hemophilia. , 0 , 249-256.   |    | 2         |
| 94  | Von Willebrand Disease: Epidemiology. , 0 , 265-271.  |    | 5         |
| 95  | Von Willebrand Disease: Biological Diagnosis. , 0 , 272-278.  |    | 1         |
| 96  | Classification and Clinical Aspects of Von Willebrand Disease. , 0 , 279-284.   |    | 0         |
| 97  | Treatment of Von Willebrand Disease: Desmopressin. , 0 , 285-288.   |    | 2         |
| 98  | Treatment of Von Willebrand Disease: Therapeutic Concentrates. , 0 , 289-295.   |    | 1         |
| 99  | Hemophilia A: Role of Factor VIII in Coagulation. , 0 , 27-33.  |    | 0         |
| 100 | Factor II. , 0 , 302-305.   |    | 0         |
| 101 | Factor V and Combined Factor V and VIII Deficiencies. , 0 , 306-310.  |    | 1         |
| 102 | Congenital Factor VII Deficiency. , 0 , 311-314.  |    | 4         |
| 103 | Factor XIII. , 0 , 328-331.   |    | 0         |
| 104 | Fibrinogen. , 0 , 332-337.  |    | 0         |
| 105 | Miscellaneous Rare Bleeding Disorders. , 0 , 338-344.   |    | 0         |
| 106 | Quality of Life in Hemophilia. , 0 , 345-350.   |    | 4         |
| 107 | Natural History of Inhibitor Development in Children with Severe Hemophilia a Treated with Factor VIII Products. , 0 , 34-38. |    | 2         |
| 108 | The Economics of Hemophilia Treatments. , 0 , 351-358.  |    | 2         |

| #   | ARTICLE  | IF | CITATIONS |
|-----|--|----|-----------|
| 109 | Comprehensive Care and Delivery of Care: The Developed World. , 0, , 359-365.    |    | 2         |
| 110 | Comprehensive Care and Delivery of Care: The Developing World. , 0, , 366-370.   |    | 2         |
| 111 | Comprehensive Care and Delivery of Care: The Global Perspective. , 0, , 371-377. |    | 1         |
| 112 | Prophylaxis. , 0, , 39-45.   |    | 1         |
| 113 | Continuous Infusion of Coagulation Products in Hemophilia. , 0, , 46-52.         |    | 0         |
| 114 | Inhibitors to Factor VIIIâ€™Immunology. , 0, , 53-58.                            |    | 1         |
| 115 | Colour Plate. , 0, , 409-412.  |    | 0         |
| 116 | Overview of Hemostasis. , 0, , 1-4.  |    | 0         |